All In Biotech

Drug Trial Radar · NCT02792218

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Oct 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 930 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

930

Actual

Start

Sep 20, 2016

Primary completion

Jul 5, 2019

Study completion Jul 20, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 7, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • Ofatumumab subcutaneous injectionDrug

    Ofatumumab 20 mg pre-filled syringes for subcutaneous injection on days 1, 7, 14, week 4 and every 4 weeks thereafter

  • Teriflunomide-matching placebo capsulesDrug

    Placebo capsule, matching in appearance to teriflunomide, taken orally once daily

  • Teriflunomide capsuleDrug

    Teriflunomide 14 mg oral capsule taken once daily

  • Matching placebo of ofatumumab subcutaneous injectionsDrug

    Matching placebo of ofatumumab subcutaneous injections on days 1, 7, 14, week 4 and every 4 weeks thereafter

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR)Time frame: Baseline up to 2.5 years

Locations

166 sites in 29 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Berkeley, California

  • Novartis Investigative Site

    Fullerton, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    Washington D.C., District of Columbia

  • Novartis Investigative Site

    Atlantis, Florida

  • Novartis Investigative Site

    Delray Beach, Florida

  • Novartis Investigative Site

    Hollywood, Florida

  • Novartis Investigative Site

    Loxahatchee Groves, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Naples, Florida

  • Novartis Investigative Site

    North Palm Beach, Florida

  • Novartis Investigative Site

    Pensacola, Florida

  • Novartis Investigative Site

    Port Charlotte, Florida

  • Novartis Investigative Site

    Sunrise, Florida

  • Novartis Investigative Site

    Vero Beach, Florida

  • Novartis Investigative Site

    West Palm Beach, Florida

  • Novartis Investigative Site

    Savannah, Georgia

  • Novartis Investigative Site

    Honolulu, Hawaii

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Northbrook, Illinois

  • Novartis Investigative Site

    Indianapolis, Indiana

  • Novartis Investigative Site

    Des Moines, Iowa

  • Novartis Investigative Site

    Kansas City, Kansas

  • Novartis Investigative Site

    Overland Park, Kansas

  • Novartis Investigative Site

    Alexandria, Louisiana

  • Novartis Investigative Site

    Baton Rouge, Louisiana

  • Novartis Investigative Site

    Clinton Township, Michigan

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    Golden Valley, Minnesota

  • Novartis Investigative Site

    Chesterfield, Missouri

  • Novartis Investigative Site

    Ozark, Missouri

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Las Vegas, Nevada

  • Novartis Investigative Site

    Latham, New York

  • Novartis Investigative Site

    Charlotte, North Carolina

  • Novartis Investigative Site

    Raleigh, North Carolina

  • Novartis Investigative Site

    Winston-Salem, North Carolina

  • Novartis Investigative Site

    Winston-Salem, North Carolina

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.